Alkahest to Present New Data from Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease at the Clinical Trials in Alzheimer’s Disease (CTAD) Conference

SAN CARLOS, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) — Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced an oral presentation of data from its phase 2a study ALK6019-201 in mild-to-moderate Alzheimer’s Disease at the 12^th Clinical Trials on Alzheimer’s Disease from December 4 – 7, 2019 in San Diego. Presentation details can be found below.

Click to view original post